Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical-proteomic classification and precision treatment strategy of chordoma

ABSTRACT: Clinical-proteomic classification and precision treatment strategy of chordoma

ORGANISM(S): Homo Sapiens

SUBMITTER: Dianwen Song

PROVIDER: PXD053631 | iProX | Thu Jul 04 00:00:00 GMT+01:00 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Clinical-proteomic classification and precision treatment strategy of chordoma.

Yin Huabin H Hu Jinbo J Gao Jianxuan J Su Tong T Jin Jiali J Jiang Cong C Yin Wenxuan W Xu Xiaowen X Chang Zhengyan Z Sun Wei W Cai Zhengdong Z Zhou Wang W Wang Ping P Lin Jun J Song Dianwen D Meng Tong T

Cell reports. Medicine 20241004 10

Chordoma is a rare and heterogeneous mesenchymal malignancy, with distinct clinical and biological behaviors. Till now, its comprehensive clinical-molecular characteristics and accurate molecular classification remain obscure. In this research, we enroll 102 patients with chordoma and describe their clinical, imageological, and histopathological features. Through tandem mass tag-based proteomic analysis and nonnegative matrix factorization clustering, we classify chordoma into three molecular su ...[more]

PMID: 39368483

Similar Datasets

A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

Project description:A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

| PRJNA1109343 | ENA

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived xenografts (PDX) and organoids (PDO) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of Micro- Organospheres (MOS) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of newly diagnosed metastatic colorectal cancer (CRC) patients using a MOS-based precision oncology pipeline reliably predicted patient treatment outcome within 14 days, a timeline suitable for guiding treatment decisions in clinic. Furthermore, MOS capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

2022-09-01 | GSE184242 | GEO

Simplified Molecular Classification of Urothelial Carcinoma via Multi-Omic Profiling: Implications for Precision Therapy

Project description:Urothelial carcinoma (UC) is a biologically heterogeneous disease and current molecular classification frameworks have limited integration into clinical decision-making. To foster precision oncology in UC, we developed a molecular classification framework of UC applicable to transcriptomic and proteomic data of non-muscle invasive bladder cancers (NMIBC), muscle-invasive bladder cancer (MIBC), and urothelial cancer cell lines. Using a whole-transcriptome self-organized map and regularized semi-supervised clustering ofn 4439 bulk NMIBC and MIBC transcriptomes and proteomes, and 33 UC cell lines, we identified three molecular UC clusters. The clusters had distinct signatures of mRNA, proteins, biological processes, metabolism, and essential driver genes. They also differed in prognosis and machine learning-predicted treatment vulnerabilities. High-risk stroma-rich cluster #1 cancers were predicted to respond to selected cytotoxic drugs, ferroptosis inducers, and PARP inhibitors. For the aggressive, fast proliferating and immune-infiltrated cluster #2 tumors with basal/squamous differentiation, cytotoxic agents and EGFR/ERBB- and MEK/ERK-targeting therapy was proposed. Cluster #3 cancers of predominantly luminal papillary phenotype, with scarce stroma and immune infiltration were enriched with NMIBC and low-risk malignancies. For cluster #3 patients, selected epigenetic drugs or EGFR/FGFR inhibitors may pose an attractive treatment option. This molecular taxonomy holds promise as a practical framework for patient stratification and therapeutic guidance in UC. Our molecular classification scheme may facilitate personalized transcriptome- and proteome-based risk assessment and therapy guidance, and the development of new cancer medication.

2026-03-11 | GSE308936 | GEO

Comparison of DNA Methylation Based Classification Models for Precision Diagnostics of Central Nervous System Tumors

Project description:As part of the advancement in therapeutic decision-making for brain tumor patients at St. Jude Children’s Research Hospital (SJCRH), we developed three robust classifiers, a deep learning neural network (NN), k-nearest neighbor (kNN), and random forest (RF), trained on a reference series DNA-methylation profiles to classify central nervous system (CNS) tumor types. The models’ performance was rigorously validated against 2,054 samples from two independent cohorts. In addition to classic metrics of model performance, we compared the robustness of the three models to reduced tumor purity, a critical consideration in the clinical utility of such classifiers. Our findings revealed that the NN model exhibited the highest accuracy and maintained a balance between precision and recall. The NN model was the most resistant to drops in performance associated with a reduction in tumor purity, showing good performance until the purity fell below 50%. Through rigorous validation, our study emphasizes the potential of DNA-methylation-based deep learning methods to improve precision medicine for brain tumor classification in the clinical setting.

2024-10-10 | GSE276299 | GEO

A mechanistic classification of clinical phenotypes in neuroblastoma

Project description:A mechanistic classification of clinical phenotypes in neuroblastoma

| PRJNA493612 | ENA

Ependymoma subpopulation lineages underlie clinical classification and outcome

Project description:Ependymoma subpopulation lineages underlie clinical classification and outcome

| PRJNA518917 | ENA

EpiGe: A cytosine methyl-genotyping PCR-based machine-learning tool for rapid classification of medulloblastoma

Project description:Molecular classification of medulloblastoma is critical for the correct treatment of this malignant paediatric brain tumour. The analysis of genome-wide DNA methylation patterns has profoundly improved diagnostic precision and classification of brain tumours. However, the implementation of DNA methylation microarrays in daily clinical practice can be time-consuming, costly and inaccessible for many centres worldwide. We aimed to develop a machine-learning decision support system for rapid and cost-effective prediction of medulloblastoma methylation class directly from quantitative PCR data.

2023-08-23 | GSE210723 | GEO

Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome

Project description:Genome-wide expression profiling was performed on 50 core needle biopsies from 18 breast cancer patients using Affymetrix GeneChip Human Genome Plus 2.0 Arrays. Global profiles of expression were characterized using unsupervised clustering methods and variance components models. Precision of predictors of breast cancer biology and clinical outcome were evaluated by interclass correlation.

2010-08-12 | E-GEOD-23593 | biostudies-arrayexpress

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived micro-organospheres (MOS) enable clinical precision oncology

| PRJNA763787 | ENA

A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues

Project description:This work presents a novel Consensus Molecular Subtypes (CMS) classifier for colorectal cancer (CRC), optimized for degraded RNA stemming from clinical formalin-fixed paraffin-embedded tissue samples.

2024-05-22 | GSE267010 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data